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Abstract 
Background: Conventional clinical biomarkers cannot accurately differentiate indolent from aggressive prostate 
cancer (PCa). We investigated the usefulness of a biomarker panel measured exclusively in biofluids for assessment of 
PCa aggressiveness.
Methods: We collected biofluid samples (plasma/serum/semen/post‑prostatic massage urine) from 98 patients 
that had undergone radical prostatectomy. Clinical biochemistry was performed and several cytokines/chemokines 
including soluble(s) TWEAK, sFn14, sCD163, sCXCL5 and sCCL7 were quantified by ELISA in selected biofluids. Also, 
the expression of KLK2, KLK3, Fn14, CD163, CXCR2 and CCR3 was quantified by real‑time PCR in semen cell sediment. 
Univariate, logistic regression, and receiver operating characteristic (ROC) analyses were used to assess the predictive 
ability of the selected biomarker panel in conjunction with clinical and metabolic variables for the evaluation of PCa 
aggressiveness.
Results: Total serum levels of prostate‑specific antigen (PSA), semen levels of sTWEAK, fasting glycemia and mRNA 
levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment constituted a panel of markers that was significantly dif‑
ferent between patients with less aggressive tumors [International Society of Urological Pathology (ISUP) grade I and 
II] and those with more aggressive tumors (ISUP grade III, IV and V). ROC curve analysis showed that this panel could 
be used to correctly classify tumor aggressiveness in 90.9% of patients. Area under the curve (AUC) analysis revealed 
that this combination was more accurate [AUC = 0.913 95% confidence interval (CI) 0.782–1] than a classical non‑inva‑
sive selected clinical panel comprising age, tumor clinical stage (T‑classification) and total serum PSA (AUC = 0.721 
95% CI 0.613–0.830).
Conclusions: TWEAK/Fn14 axis in combination with a selected non‑invasive biomarker panel, including conven‑
tional clinical biochemistry, can improve the predictive power of serum PSA levels and could be used to classify PCa 
aggressiveness.
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Background
Prostate cancer (PCa) is the fourth most common cancer 
in both sexes collectively and the second most common 
cancer in men [1]. PCa is a curable disease if detected 
at an early stage and there are several viable therapeutic 
options available; however, many patients fail to respond 
to first-line treatments. Conventional clinical prognos-
ticators of PCa severity and progression include digi-
tal rectal examination, serum prostate-specific antigen 
(PSA) measurement, and transrectal ultrasound-guided 
histopathological staging [2]. PSA is encoded in humans 
by the kallikrein-3 (KLK3) gene [3] and its secreted pro-
tein is a pre-propeptide that can be activated by human 
glandular kallikrein-2 protease, encoded by KLK2 [4]. 
While the application of PSA serum testing as a screen-
ing tool for PCa has reduced mortality rates and the 
prevalence of advanced-stage disease at diagnosis, there 
is continuing debate over its efficacy as a specific marker 
for diagnosis and prognosis [5]. Accordingly, robust bio-
markers are needed for the early screening of patients at 
risk of PCa.
Liquid biopsy is a promising non-invasive modality 
for molecular profiling in cancer, enabling the assess-
ment of circulating molecules in various biological fluids 
for biomarker discovery [6]. Moreover, when combined 
with multi-marker analysis, liquid biopsy is a potentially 
powerful platform for prognosis and early assessment of 
treatment failure.
TNF-like weak inducer of apoptosis (TWEAK) and 
fibroblast growth factor-inducible molecule 14 (Fn14) 
are a ligand/receptor pair belonging to the TNF recep-
tor superfamily. TWEAK is synthesized as a membrane-
anchored protein (mTWEAK) that is released into 
circulation in a soluble form (sTWEAK) after process-
ing by a furin protease. Both sTWEAK and mTWEAK 
function through engagement with Fn14 [7]. TWEAK 
has pleiotropic effects on different cell functions, medi-
ating pro-inflammatory and pro-angiogenic activity, and 
stimulating invasion, migration and survival [8, 9]. Fn14 
is expressed at relatively low levels in normal tissues, 
but is significantly upregulated locally following tissue 
injury or disease, where it mediates tissue remodeling [7]. 
Interestingly, Fn14 overexpression promotes androgen-
independent PCa progression and correlates with poor 
treatment outcome [10]. Many TNF receptors undergo 
proteolytic cleavage to generate soluble forms that are 
shed into biofluids, and a recent study reported the 
presence of high levels of soluble Fn14 (sFn14) in urine 
samples of patients with kidney injury [11], pointing to 
sFn14 as a potential biomarker for progression of kidney 
disease.
In addition to binding Fn14, sTWEAK can also bind 
to the CD163 (cluster of differentiation 163) receptor, 
which acts as a scavenger receptor since its binding does 
not transduce intracellular signals but instead mediates 
the elimination of sTWEAK, contributing to its degrada-
tion [12]. CD163 is expressed exclusively on monocytes/
macrophages and is tightly regulated by inflammatory 
responses and anti-inflammatory signals [13]. Similar to 
Fn14, CD163 not only exists as a membrane-bound form, 
but is also released into circulation as a soluble form 
(sCD163), and is a sensitive indicator of macrophage acti-
vation [14]. Interestingly, the presence of  CD163+ mac-
rophages is strongly associated with less favorable clinical 
and pathological features in breast cancer [15].
Several chemokines are known to play key roles in the 
development and progression of PCa [16]. For example, 
the apoptosis-induced chemokine CXCL5 and its recep-
tor CXCR2 have been reported to accelerate inflamma-
tion and growth of prostate tumor metastases in bone 
[17]. Moreover, CXCL5/CXCR2 expression was found 
to correlate with Gleason grading and clinical pathologic 
stages [18]. Another study examined the CCL7/CCR3 
axis in a mouse model of PCa and obesity, specifically in 
the periprostatic adipose tissue surrounding the tumor, 
finding that this tissue secretes CCL7, which in turn 
stimulates the migration of CCR3-expressing tumor cells 
[19]. Notably, depletion of tumor CCR3 completely abol-
ished the ability of obesity to promote tumor metastasis 
[15]. Crosstalk between CCL7 and CCR3 has also been 
found to promote colon cancer metastasis [20].
Because the aforementioned biomolecules, TWEAK, 
CXCL5 and CCL7 and their respective receptors (Fn14, 
CXCR2 and CCR3) as well as PSA-related genes (KLK3 
and KLK2) are known to be linked to tumorigenesis and 
could therefore provide a growth advantage to tumors, 
we designed a study to quantify and examine these 
selected biomarkers in several biofluids from patients 




This retrospective study included 98 consecutive patients 
with PCa who had undergone radical prostatectomy by 
open surgery—laparoscopic or robotic surgery (intra-
peritoneal or extraperitoneal)—with or without bilateral 
ilio-obturator lymphadenectomy, according to estimated 
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risk of lymphadenopathy based on the Briganti nomo-
gram [21]. Surgeries were performed at the University 
Hospital Joan XXIII, Tarragona, between 2015 and 2018. 
Grades, groups and stage of the tumors were determined 
according to the 2014 International Society of Urologi-
cal Pathology (ISUP) Gleason Grading (GG) and Tumor 
Node Metastases (TNM) classification, respectively [22, 
23]. We stratified patients according to ISUP GG into two 
categories: low-risk (ISUP group I and II) and high-risk 
(ISUP groups III, IV and V).
The study was performed according to the provisions 
of the Declaration of Helsinki, was approved by our local 
ethics committee, and adhered to current legal regula-
tions (Biomedical Research Law 14/2007, Royal Decree 
of Biobanks 1716/2011, Organic Law 15/1999 of Sep-
tember 13 Protection of Personal Data). All participants 
provided written informed consent prior to their inclu-
sion. Clinical parameters regarding tumor aggressive-
ness and metabolic status of all patients were recorded. 
All methods were performed in accordance with the rel-
evant guidelines and regulations. Inclusion criteria were 
as follows: patients older than 18  years diagnosed with 
PCa by prostate biopsy in our center or any other, treated 
by radical prostatectomy in our center, and with signed 
informed consent for the study. Exclusion criteria were 
patients with previous history of cancer, patients older 
than 75  years, and those who had received any prior 
treatment before radical prostatectomy for PCa. Body 
mass index (BMI) was measured using standard proce-
dures and World Health Organization criteria.
Biofluid processing
Post digital rectal examination urine
First-catch voided urine (30  mL) was collected after 
attentive digital rectal examination and prior to pros-
tate biopsy or surgical intervention. Urine samples were 
immediately centrifuged (2000×g, 10  min, 4  °C), and 
stored at − 80 °C for further examination.
Serum
After a fast of at least 12 h, blood was obtained from the 
antecubital vein. Samples were centrifuged for 15  min 
at 5000×g and stored at − 80  °C for further deter-
minations. All clinical biochemistry variables were 
calculated according to standardized methods. The 
homeostatic model assessment-insulin resistance index 
(HOMA-IR) was calculated using the formula: (glucose 
[mmol/L] × insulin [mU L−1])/22.5).
Semen
Ejaculate specimens from 52 patients were centrifuged at 
2000×g for 15 min at 22 °C to separate spermatozoa from 
semen plasma. The supernatant (semen plasma) was then 
aliquoted into 100 µL aliquots and frozen at − 80 °C until 
further processing. The cell sediment was washed once 
with one volume of phosphate buffered saline and stored 
frozen at − 80 °C until further RNA extraction.
Enzyme‑linked immunosorbent assays
Levels of sTWEAK, sCD163, sCXCL5, sCCL7 in biofluids 
were determined in duplicate using commercially availa-
ble human enzyme-linked immunosorbent assay (ELISA) 
DuoSet Kits (R&D Systems Europe, Abingdon, UK). For 
sFn14 quantification, we used commercial ELISA kits 
from Aviva Systems Biology (Bionova Cientifica, Barce-
lona, Spain). Urine biomarker levels were normalized to 
creatinine urine levels, whereas semen biomarker levels 
were normalized to total protein measured by the bicin-
choninic acid assay method (Pierce™ BCA Protein Assay 
Kit, Thermo Fisher Scientific, Barcelona, Spain).
Quantitative reverse transcription‑polymerase chain 
reaction
RNA from semen cell sediments was extracted using 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA) and 
quantified with a NanoDrop device (NanoDrop Tech-
nologies, Wilmington, DE, USA). cDNA was synthe-
sized from 500 ng of total RNA using the High Capacity 
cDNA reverse transcription kit (Applied Biosystems, 
Foster City, CA, USA). Real-time quantitative PCR was 
performed on a 7900HT fast real-time PCR system using 
commercial Taqman assays (Applied Biosystems) for the 
following genes: Fn14, CD163, KLK2, KLK3, CXCR2 and 
CCR3. The cycle threshold  (Ct) value for each sample was 
normalized to the expression of PPIA (cyclophilin A), 
which showed no significant gene expression differences 
between the compared groups of patients. SDS software 
2.3 and RQ Manager 1.2 (Applied Biosystems) were used 
to analyze the results with the comparative  Ct method 
 (2−∆∆Ct). All data were expressed as an n-fold difference 
relative to the calibrator (a mixture of the RNA from 4 
different patients was used as a calibrator sample).
Statistical analysis
For clinical and anthropometrical variables, data are 
expressed as mean ± standard deviation (SD). Before sta-
tistical analysis, normal distribution and homogeneity of 
the variances was evaluated using Levene’s test, and then 
variables were log-transformed when necessary. Differ-
ences between patients according to ISUP GG—low-risk 
(Group I and II) and high-risk ISUP GG (Group III, IV 
and V)—were tested with the Mann–Whitney U test 
for non-normally distributed data. A p-value less than 
0.05 was considered statistically significant. Logistic 
regression analysis and receiver-operating characteristic 
(ROC) curves were generated for selected variables. The 
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statistical software SPSS Statistics 21.0 (IBM, Madrid, 
Spain) package and the R software (http://cran.r-proje 
ct.org) were used for analysis. For generation of chord 
diagrams, the Circos Table Viewer was employed (http://
mkweb .bcgsc .ca).
Results
Study population and informative rate
Table 1 summarizes the patients’ pathological and clini-
cal characteristics. The study included 98 consecutive 
patients with PCa who had undergone radical prostatec-
tomy by open surgery. Urological history and comple-
mentary examinations were as follows: prostate volume 
measured by transrectal ultrasound grade and stage of 
the biopsy taken from the tumors determined in accord-
ance with the ISUP GG criteria and TNM classification, 
respectively [22]. With respect to BMI, 51.6% of the 
patients were overweight, 26.7% were obese and 21.7% 
were classified as lean. PSA was measured as per stand-
ard clinical practice and results showed that 61.8% of 
patients had levels between 4 and 10  ng/mL, whereas 
30.9% had levels above 10  ng/mL. Regarding ISUP GG 
criteria, 63.3% of the patients were classified as low-risk 
(group I and II) and 36.7% were high-risk (group III, IV 
and V). From the 93 patients with clinical-tumoral stage 
T2, 25.5% were upgraded after surgery; then, 70.4% were 
classified as ≤ T2 and the remaining 29.6% were classified 
as T3 or T4.
Correlation analysis of biofluid biomarkers with clinical 
and metabolic parameters of the study population
Analysis of correlation by Spearman’s bivariate correla-
tion test, considering only the significant associations, is 
shown in Fig. 1. We found a positive association between 
urine sTWEAK levels and urine sFn14 (r = 0.721, 
p < 0.001) and sCD163 (r = 0.417, p ˂  0.001) levels, 
whereas sCXCL5 urine levels correlated with serum total 
PSA levels (r = 0.250, p = 0.018). Similarly, sFn14 in urine 
was positively related to urea levels (r = 0.299, p = 0.007). 
No other associations were observed between biomark-
ers in urine and those in serum or semen.
Regarding the associations of biomarkers in semen, we 
found that semen plasma sTWEAK levels were positively 
associated with sFn14 (r = 0.405, p = 0.003), sCXCL5 
(r = 0.362, p = 0.009) and KLK2 mRNA levels in semen 
cell sediment (r = 0.552, p < 0.001), and negatively associ-
ated with CCR3, CD163 and Fn14 mRNA levels in semen 
cell sediment (r = -0.404, p = 0.003; r = − 0.333, p = 0.041; 
Table 1 Clinical and pathological characteristics of the cohort
N number of patients, SD standard deviation, BMI body mass index, ISUP GG ISUP Grade Groups based on the Gleason score as follows: (Gleason score ≤ 6 group I; 
3 + 4=7 group II; 4 + 3=7 group III; 4 + 4=8 group IV; and 9–10 group V); T‑stage tumor category; N lymph node category
Mean ± SD N
Age (years) 63.5 ± 6.5 98
Prostatic volume (c.c) 44.4 ± 22.4 98
Testosterone (nmol/L) 13.9 ± 4.9 98
Total PSA (ng/mL) 9.7 ± 8.20 98
N (%)
BMI (kg/m2) < 25 21 (21.7)
25–29.99 50 (51.6)
≥ 30 26 (26.7)
Total PSA (µg/L) < 4 7 (7.2)
4–10 60 (61.9)
> 10 30 (30,9)
ISUP GG
 Low risk Group I 38 (38,8)
Group II 24 (24,5)
 High risk Group III 19 (19.3)
Group IV 10 (10.2)
Group V 7 (7.2)
T pathological stage ≤ T2a 69 (70.4)
T3, T4 29 (29,6)
No pathological stage NX 53 (55.8)
N0 36 (37.9)
N1 6 (6.3)
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r = − 0.413, p < 0.001, respectively). Also, sCD163 lev-
els were positively associated with sCXCL5 (r = 0.502, 
p < 0.001) and sCCL7 levels (r = 0.601, p < 0.001), and a 
weak positive association was found with its mRNA level 
in semen cell sediment (r = 0.328, p = 0.034). The levels 
of sFn14 were associated positively with KLK2 and KLK3 
mRNA levels in semen cell sediment (r = 0.556, p < 0.001; 
r = 0.494, p < 0.001, respectively) and with serum lipid 
markers including cholesterol and triglycerides (r = 0.346 
p = 0.012; r = 0.348 p = 0.016, respectively), and nega-
tively associated with CXCR2 and CCR3 mRNA levels in 
semen cell sediment (r = − 0.378, p = 0.012; r = − 0.473, 
p = 0.001). Finally, sCXCL5 levels in semen were posi-
tively associated with sCCL7 levels (r = 0.563 p < 0.001) 
and with KLK2 mRNA levels in semen cell sediment 
(r = 0.447, p = 0.003).
Fig. 1 Spearman correlation matrix. Correlation map plotted using significance levels for Spearman test performed with relevant clinical and 
biomarker data from all studied patients. Positive correlations are displayed in graded blue colors and negative correlations in graded red colors. 
Correlations with p‑value ≥ 0.05 are considered as insignificant and are left blank. Color intensity and the size of the circle are proportional to the 
correlation coefficients. In the right side of the correlogram, the color legend shows the correlation coefficients and the corresponding colors. 
BMI body mass index, HOMA-IR homeostatic model assessment for insulin resistance, HbA1c hemoglobin A1c, HDL high‑density lipoprotein, LDL 
low‑density lipoprotein, AST aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyltransferase, SHBG sex hormone‑binding 
globulin, PSA prostate‑specific antigen, TWEAK tumor necrosis factor‑like weak inducer of apoptosis, CD163 cluster of differentiation 163, Fn14 
fibroblast growth factor‑inducible 14, CXCL5 C‑X‑C motif chemokine 5, CCL7 chemokine (C‑C motif ) ligand 7, CXCR2 C‑X‑C motif chemokine 
receptor 2, CCR3 C‑C chemokine receptor type 3, KLK2 kallikrenin‑2 gene, KLK3 Kallikrenin‑3 gene
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Analysis of biomarkers in serum showed that sTWEAK 
and sCXCL5 were positively associated with sCCL7 lev-
els (r = 0.309, p = 0.006; r = 0.371, p = 0.001, respectively). 
Also, sCD163 was associated with glycemic parameters 
such as fasting glycemia (r = 0.243, p = 0.031), insu-
lin (r = 0.365, p = 0.001), HOMA-IR index (r = 0.387, 
p < 0.001) and  HbA1c (r = 0.271, p = 0.016). No asso-
ciations between biomarkers in serum and semen were 
observed.
Regarding the mRNA levels of the selected biomark-
ers in semen cell sediment, we observed a positive asso-
ciation between KLK2 and KLK3 (r = 0.603, p < 0.001), 
whereas KLK2 was negatively associated with CXCR2, 
CCR3 and Fn14 (r = − 0.442, p = 0.003; r = − 0.635, 
p < 0.001; r = − 0.520, p < 0.001, respectively). Addition-
ally, CXCR2 was strongly associated with CCR3 and Fn14 
(r = 0.918, p < 0.001; r = 0.725, p < 0.001). Of note, choles-
terol serum levels had a weak positive association with 
mRNA levels of KLK2 and KLK3 (Fig. 1).
Univariate analysis of biofluid biomarkers and clinical 
and metabolic parameters
We next compared these variables in patients classi-
fied according to ISUP group: low-risk (group I and II) 
and high-risk (group III, IV and V). Differences in clini-
cal and metabolic characteristics and biomarker profiles 
in semen serum, urine and semen cell sediment (gene 
expression) were recorded in both groups (Table 2).
As expected, univariate analysis showed that total 
serum PSA was significantly higher in the high-risk 
group than in the low-risk group (p = 0.003) (Fig.  2a). 
sTWEAK levels in semen were significantly lower in the 
high-risk group than in the low-risk group (p = 0.003) 
(Fig.  2b). Regarding gene expression levels, we found 
higher mRNA expression of KLK2 in the low-risk group 
than in the high-risk group (p = 0.05). Of note, there was 
a trend for higher Fn14, CXCR2 and CCR3 gene expres-
sion levels in semen cell sediment in the high-risk group 
relative to the low-risk group, but this did not reach 
statistical significance (p = 0.077, p = 0.089, p = 0.069, 
respectively) (Fig.  2c). No significant differences were 
detected between compared groups regarding anthro-
pometric parameters, lipid, hepatic, renal and hormonal 
profiles. By contrast, serum glucose levels were signifi-
cantly higher in the high-risk group than in the low-risk 
group (p = 0.05) (Fig. 2d).
Notably, the evaluation of correlations among anthro-
pometric and metabolic parameters in individuals with 
less aggressive tumors (group I and II) compared with 
those with more aggressive tumours (groups III, IV and 
V) showed clear differences between both groups of sub-
jects (Fig. 3).
Potential relevance of biofluid biomarkers 
in the stratification of PCa aggressiveness
To evaluate the performance of a selected biomarker 
panel (Fig.  2) as a predictor of PCa aggressiveness, we 
performed ROC analysis for total PSA in serum, one of 
the primary differentiator variables of patients stratified 
according to ISUP GG risk categories. The diagnostic 
accuracy of this signature had an area under the curve 
(AUC) of 0.716 (95% confidence interval [CI] 0.612–
0.820), with 80% sensitivity and 48.4% specificity, and 
could correctly classify 68.4% of patients (Fig. 4a).
When we used a panel of routinely used non-invasive 
clinical variables for patient classification in a logis-
tic regression model, by combining age, clinical stage 
(T-classification) and total PSA levels in serum, we 
obtained a model that allowed the correct identification 
of 72.9% of patients. The ROC curve obtained using the 
non-invasive clinical panel had an AUC of 0.721 (95% CI 
0.613–0.830), with 80% sensitivity and 48.3% specificity 
(Fig. 4b).
As we observed differences in some of the abovemen-
tioned biomarkers between ISUP GG risk categories, we 
tested the ability of a selected biomarker panel to predict 
PCa aggressiveness. A logistic regression model helped to 
identify the following determinants: sTWEAK in semen, 
fasting glycemia and the expression levels of Fn14, KLK2, 
CXCR2 and CCR3 in semen cell sediment. This analy-
sis could correctly identify 81.1% of patients according 
to histologic Gleason aggressiveness. The ROC curve 
obtained with this non-invasive biomarker panel had an 
AUC of 0.845 (95% CI 0.694–0.997), with 80% sensitivity 
and 76.2% specificity, enhancing the specificity of these 
parameters as compared with the aforementioned non-
invasive classical clinical panel (Fig. 4c).
We also assessed the power of classification by combin-
ing the selected non-invasive biomarker panel plus total 
PSA serum levels, and the resulting logistic regression 
model outperformed the other models, with patient iden-
tification of 90.9%, an AUC of 0.913 (95% CI 0.782–1), 
and with 80% sensitivity and 85.7% specificity (Fig. 4d).
Discussion
There is a desperate need to correctly identify patients 
with PCa and aggressive disease to guide treatment deci-
sions and to avoid unnecessary prostate procedures. 
Biomarkers are used extensively in clinical practice to 
predict the presence of PCa and to distinguish aggressive 
from indolent forms [24]. While circulating serum total 
PSA is used extensively for general screening to diag-
nose the presence of PCa, new biomarkers are needed for 
the implementation of more personalized diagnosis and 
management of PCa.
Page 7 of 13Ruiz‑Plazas et al. J Transl Med          (2019) 17:307 
Table 2 Anthropometric, clinical and biochemical variables classified according to ISUP GG patient classification
ISUP GG classification
Low risk (group I and II) High risk (group III, IV and V) p‑value
Mean ± SD Mean ± SD
Anthropometric parameters
 Age (years) 62.82 ± 6.8 64.55 ± 5.82 0.320
 BMI (kg/m2) 28.23 ± 4.05 27.94 ± 3.54 0.665
 Prostatic volume (cc) 45.71 ± 25.96 43.5 ± 19.52 0.716
Glycemic profile
 Glucose (mmol/L) 5.90 ± 1.23 6.65 ± 2.35 0.050
 Insulin (pmol/L) 95.42 ± 60.84 89.73 ± 48.41 0.847
 HOMA‑IR 3.75 ± 2.92 3.92 ± 2.76 0.795
 HbA1c (%) 5.77 ± 0.67 6.01 ± 0.86 0.152
Lipid profile
 Cholesterol (mmol/L) 5.02 ± 1.06 4.93 ± 1.01 0.609
 HDL cholesterol (mmol/L) 1.49 ± 0.71 1.35 ± 0.39 0.484
 LDL cholesterol (mmol/L) 3.23 ± 1.29 2.84 ± 0.88 0.148
 Triglycerides (mmol/L) 1.40 ± 0.74 1.63 ± 0.99 0.526
Hepatic profile
 AST (µkat/L) 0.38 ± 0.19 0.32 ± 0.07 0.104
 ALT (µkat/L) 0.40 ± 0.21 0.36 ± 0.11 0.816
 GGT (µkat/L) 0.72 ± 0.88 0.68 ± 0.50 0.783
Renal profile
 Uric acid (µmol/L) 373.57 ± 88.63 463.39 ± 559.75 0.595
 Urea (mmol/L) 13.99 ± 3.34 14.44 ± 5.40 0.922
 Creatinine (μmol/L) 83.98 ± 1.77 77.79 ± 2.19 0.187
Hormonal profile
 SHBG (nmol/L) 46.64 ± 50.65 38.93 ± 16.71 0.756
 Testosterone (nmol/L) 14.22 ± 4.62 12.88 ± 5.80 0.158
Tumoral markers
 Total PSA (μg/L) 7.64 ± 4.42 13.14 ± 11.47 0.003
Biofluid biomarker profile
 Semen cytokines (pg/mg of total protein)
  sTWEAK 989.07 ± 624.08 550.54 ± 380.25 0.003
  sCD163 1449.03 ± 2060.7 1392.09 ± 1265.89 0.391
  sFn14 645.31 ± 434.45 609.99 ± 413.28 0.781
  sCXCL5 360.23 ± 376.07 212.72 ± 240.72 0.179
  sCCL7 3.09 ± 3.34 3 ± 2.69 0.767
 Serum cytokines (pg/mL)
  sTWEAK 1118.74 ± 344.32 1331.08 ± 830.51 0.225
  sCD163 346.68 ± 286.15 349.46 ± 276.29 0.976
  sCXCL5 1234.89 ± 630.15 1346.42 ± 703.23 0.439
  sCCL7 2.6 ± 17.62 23.49 ± 107.42 0.508
 Urine cytokines (pg/mg of creatinine)
  sTWEAK 199.62 ± 257.43 128.24 ± 151.58 0.723
  sCD163 166.07 ± 804.1 1173.09 ± 3368.52 0.401
  sFn14 182.5 ± 287.53 159.69 ± 236.24 0.479
  sCXCL5 132.97 ± 142.43 161.98 ± 165.27 0.423
 Semen cell sediment gene expression (arbitrary units,  2−∆∆Ct)
  KLK2 1.12 ± 0.41 0.82 ± 0.45 0.050
  KLK3 1.16 ± 0.75 1.02 ± 0.74 0.529
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To identify new biomarkers for PCa in liquid biopsies, 
in the present work we measured the circulating lev-
els of sTWEAK and its receptors sFn14 and sCD163, in 
addition to two chemokines, CXCL5 and CCL7, all of 
which are closely related to prostate tumorigenesis [17, 
19] but never analyzed in human PCa liquid biopsies. 
Table 2 (continued)
ISUP GG classification
Low risk (group I and II) High risk (group III, IV and V) p‑value
Mean ± SD Mean ± SD
  CXCR2 2.68 ± 3.6 4.03 ± 3.7 0.089
  CCR3 2.53 ± 3.23 6.31 ± 8.1 0.069
  CD163 6.37 ± 6.57 5.68 ± 5.54 0.796
  Fn14 4.15 ± 2.82 8.52 ± 7.69 0.077
BMI, Body mass index; cc, centiliters; HOMA‑IR, homeostatic model assessment for insulin resistance; HbA1c, hemoglobin A1c; HDL, high‑density lipoprotein; LDL, 
low‑density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma glutamyltransferase; SHBG, sex hormone‑binding globulin; PSA, 
prostate specific antigen; TWEAK, tumor necrosis factor‑like weak inducer of apoptosis; CD163, cluster of differentiation 163; Fn14, fibroblast growth factor‑inducible 
14; CXCL5, C‑X‑C motif chemokine 5; CCL7, chemokine (C‑C motif ) ligand 7; CXCR2, C‑X‑C motif chemokine receptor 2; CCR3, C‑C chemokine receptor type 3; KLK2, 
Kallikrenin‑2 gene; KLK3, Kallikrenin‑3 gene
Fig. 2 Biomarker panel for prediction of prostate cancer aggressiveness. Box plot representing significant changes of biomarker levels in different 
biofluids: a Serum total PSA, b sTWEAK semen levels, c mRNA levels in semen cell sediment of: Fn14, KLK2, CXCR2 and CCR3, and d fasting glucose 
levels. Values of each biomarker are expressed as mean ± SD. Differences between patients according to Gleason stage coded into two categories: 
low‑risk ISUP GG (group I and II) or high‑risk ISUP GG (group III, IV and V) were tested with the Mann–Whitney U test for non‑normally distributed 
data. p‑values less than 0.05 were considered statistically significant
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Additionally, we evaluated the expression of their related 
receptors (Fn14, CD163, CXCR2, and CCR3) in semen 
cell sediment as well as gene expression of the PSA-
related genes KLK2 and KLK3, as possible biomarkers for 
PCa aggressiveness.
In the context of cancer, circulating levels of sTWEAK 
have previously been described as a biomarker in head 
and neck cancer, where low serum levels of sTWEAK 
were found to be related to reduced survival rate [25, 26], 
pointing to sTWEAK levels as a possible non-invasive 
biomarker in this patient group. To the best of our knowl-
edge, no study has reported on the potential of sTWEAK 
as a PCa biomarker; however, it is important to consider 
that a pro-tumorigenic role of the TWEAK/Fn14 axis 
has previously been evaluated in vitro in several PCa cell 
types [8, 10, 27, 28].
Bivariate correlation analysis showed that semen levels 
of sTWEAK and sFn14 were positively related and also 
correlated with KLK2 mRNA expression in semen cell 
sediment. KLK2 is a member of the Kallikrein family of 
secreted serine proteases, which are associated with pro-
static tissue [29]. KLK2 is highly expressed in prostate 
tumor cells and might be a prognostic marker for PCa 
risk [30]. Also, the expression of KLK2 is highly corre-
lated with that of KLK3 [29], which allowed us to deter-
mine the prostate epithelial cell content in semen [3], 
suggesting that the positive correlation of sTWEAK and 
sFn14 in semen could be directly related to prostate cell 
epithelium.
Interestingly, a strong positive association was observed 
between sCD163 and sCXCL5 and sCCL7 in semen. All 
of these molecules are known to be expressed mainly in 
macrophages [31]. Additionally, sCD163 is specifically 
related to alternative “M2-type” macrophages, which are 
abundantly found in cancer [32], whereas CXCL5 pro-
tein expression levels are concordant with prostate tumor 
Fig. 3 Chord diagram showing differences in correlations between variables across individuals showing differential ISUP GG risk: low‑risk ISUP GG 
(group I and II) and high‑risk ISUP GG (group III, IV and V). Segments in circles indicate variables analyzed (see below for abbreviations employed), 
chords linking variables indicate significant correlations (at least p < 0.05) according to Spearman rank correlations, while chord thickness is directly 
proportional to correlation coefficient. For clarity, only positive correlations are shown. TEST testosterone, CREAT creatinine, HOMA-IR homeostatic 
model assessment for insulin resistance, HbA1c hemoglobin A1c, HDL high‑density lipoprotein, LDL low‑density lipoprotein, CHOL cholesterol, AST 
aspartate aminotransferase, ALT alanine aminotransferase, GGT gamma glutamyltransferase, PSA prostate‑specific antigen, TWEAK tumor necrosis 
factor‑like weak inducer of apoptosis, CD163 cluster of differentiation 163, Fn14 fibroblast growth factor‑inducible 14, CXCL5 C‑X‑C motif chemokine 
5, CCL7 chemokine (C‑C motif ) ligand 7, CXCR2 C‑X‑C motif chemokine receptor 2, CCR3 C‑C chemokine receptor type 3, KLK2 kallikrenin‑2 gene, 
KLK3 kallikrenin‑3 gene
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progression. Furthermore, both CD163 and CXCL5 are 
highly associated with inflammatory infiltrates, which are 
frequently detected in the lumen of malignant prostate 
glands [33].A relationship between the TWEAK/Fn14 
axis and CD163 was also found in urine.
In serum, sTWEAK levels positively correlated 
with sCCL7 and sCXCL5, and it is known that high 
expression of CXCL5 is closely related to cancer 
progression [34–36], which is in line with the associa-
tion we observed in our cohort between PSA levels and 
sCXCL5 in urine. Of particular note is the association 
found between serum levels of sCD163 and glycemia-
related variables (insulin, HOMA-IR index and fasting 
glycemia), corroborating previous findings for this bio-
marker in the context of diabetes and altered glucose 
metabolism [37, 38].
Fig. 4 Biomarker models for prediction of prostate cancer aggressiveness. Receiver‑operating characteristic curve (ROC) analysis as assessed 
according to low‑risk ISUP GG (group I and II) and high‑risk ISUP GG (group III, IV and V). a Total PSA, b Clinical panel (Age, T‑classification, total PSA), 
c Biomarker panel (sTWEAK in semen, glucose levels in serum and mRNA levels of Fn14, KLK2, CXCR2 and CCR3 in semen cell sediment), d Biomarker 
panel in combination with total PSA
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In serum, sTWEAK levels were unchanged between 
the high- and low-risk patient groups. Serum sTWEAK 
levels are reduced in obesity [39]. In our cohort, 51.6% of 
the patients were overweight and 26.7% were obese, but 
no association was observed between sTWEAK serum 
levels and BMI. However, we found that semen levels of 
sTWEAK were significantly altered according to Gleason 
histologic aggressiveness. The reduction in sTWEAK lev-
els in semen in high-risk patients was accompanied by a 
tendency for an increase in Fn14 mRNA levels in semen 
cell sediment. This finding might indicate an active pro-
cess of ligand–receptor interaction in this microenvi-
ronment, in which the ligand–receptor complex must 
be internalized, thereby reducing ligand availability and 
favoring the process of proliferation and migration, as 
described in PCa cells in vitro mediated by the TWEAK/
Fn14 axis [10, 28].
Interestingly, the mRNA expression levels of CCR3 
and CXCR2 in semen cell sediment showed a similar 
behavior to Fn14 mRNA in the ISUP high-risk patients, 
which might indicate a higher activity of the respective 
ligands CCL7 and CXCL5 at this site, although no signifi-
cant changes were found for these soluble chemokines 
in our patients between high- and low-risk groups. We 
observed a decreased expression of KLK2 in semen cell 
sediment in high-risk patients, whereas PSA levels were 
higher. Although a positive relationship was expected, we 
do not have a clear explanation for this finding. Of note, 
it has been reported that KLK2 expression represents 
only 50% of total PSA [40].
Concerning the profiles of metabolic and biochemi-
cal parameters (lipidic, hepatic, renal and hormonal), 
we found differences only in the levels of serum glucose 
between low- and high-risk PCa patients in our cohort, 
with elevated levels of glucose in the latter group. This 
is consistent with a previous finding of an association 
between serum glucose levels and disease outcome in 
colorectal, breast, bladder, pancreatic and PCa patients 
[41]. By contrast, correlation patterns between anthro-
pometric and metabolic variables across individuals 
with high-risk and low-risk were markedly different, as 
demonstrated by chord diagram analysis, pointing to an 
intrinsic metabolic behaviour in these groups. Serum 
cholesterol may be related to PCa biology [42, 43], in this 
sense, we observed an association between cholesterol 
levels and KLK3 and KLK2 gene expression, both related 
to PSA protein levels.
While PSA provides a sensitive marker for PCa diagno-
sis, it is not only confined to PCa, hence it cannot be used 
alone as a diagnostic PCa biomarker [44]. In our study, 
ROC curve analysis using PSA alone had no advantage 
in its predictive ability, either alone or combined with a 
classical clinical panel (age, T-classification, total PSA). 
These results prompted us to question whether we could 
establish another suitable non-invasive biomarker panel 
for PCa aggressiveness by inputting a combination of 
the new biomarkers studied. Indeed, ROC curve analy-
sis demonstrated that this new non-invasive biomarker 
panel comprising sTWEAK in semen, glucose levels 
in serum and mRNA levels of Fn14, KLK2, CXCR2 and 
CCR3 in semen cell sediment had a better AUC than PSA 
and even the classical non-invasive clinical panel (age, 
T-classification, total PSA) (AUCs of 0.845, 0.716 and 
0.721, respectively), and could classify patients accord-
ing to PCa aggressiveness with higher specificity when 
compared with either total PSA classification or when 
using the non-invasive classical clinical panel (specificity 
of 76.2%, 48.4% and 48.3%, respectively). Moreover, the 
combination of the above biomarker panel to supplement 
total serum PSA improves the AUC stratification (91.3%) 
of tumor aggressiveness, as classified by ISUP high-risk 
or low-risk. This new panel (biomarker panel plus total 
serum PSA) could be used to correctly classify tumor 
aggressiveness in 90.9% patients with higher specificity 
(85.7%). Although our findings are encouraging, a larger 
cohort will be needed to support the biomarker panel for 
positive diagnosis.
Conclusions
A biofluid signature comprising sTWEAK in semen, 
serum fasting glycemia and the mRNA levels of Fn14, 
KLK2, CXCR2 and CCR3 in semen cell sediment, com-
bined with total serum PSA levels, represents a non-inva-
sive biomarker panel with high negative predictive value 
that can be used to classify PCa aggressiveness.
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